Author:
Iemolo Francesco,Pizzo Federica,Albeggiani Giuseppe,Zizzo Carmela,Colomba Paolo,Scalia Simone,Bartolotta Caterina,Duro Giovanni
Abstract
Abstract
Background
Fabry disease is an X-linked inherited metabolic condition where the deficit of the α-galactosidase A enzyme, encoded by the GLA gene, leads to glycosphingolipid storage, mainly globotriaosylceramide. To date, more than 600 mutations have been identified in human GLA gene that are responsible for FD, including missense and nonsense mutations, small and large deletions. Such mutations are usually inherited, and cases of de novo onset occur rarely.
Case presentation
In this article we report an interesting case of a 44-year-old male patient suffering from a severe form of Fabry disease, with negative family history. The patient showed signs such as cornea verticillata, angiokeratomas, cardiac and neurological manifestations, an end-stage renal disease and he had low α-galactosidase A activity. We detected, in this subject, the mutation c.493 G > C in the third exon of the GLA gene which causes the amino acid substitution D165H in the protein. This mutation affects the amino acid - belonging to the group of buried residues - involved, probably, in the preservation of the protein folding. Moreover, studies of multiple sequence alignment indicate that this amino acid is highly conserved, thus strengthening the hypothesis that it is a key amino acid to the enzyme functionality.
The study of the relatives of the patient showed that, surprisingly, none of the members of his family of origin had this genetic alteration, suggesting a de novo mutation. Only his 11-year-old daughter - showing acroparaesthesias and heat intolerance with reduced enzymatic activity - had the same mutation.
Conclusions
We suggest that a non-inherited mutation of the α-galactosidase A gene is responsible for Fabry disease in the patient who had reduced enzyme activity and classical clinical manifestations of the disease. In a family, it is rare to find only one Fabry disease affected subject with a de novo mutation. These findings emphasize the importance of early diagnosis, genetic counselling, studying the genealogical tree of the patients and starting enzyme replacement therapy to prevent irreversible vital organ damage that occurs during the course of the disease.
Publisher
Springer Science and Business Media LLC
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference21 articles.
1. Germain DP: Fabry disease. Orphanet J Rare Dis. 2010, 5 (30):
2. Desnick RJ, Ioannou YA: α-galactosidase a deficiency: fabry disease. The Metabolic and Molecular Basis of Inherited Disease. Edited by: Scriver CR, Beaudet AL, Sly WS, Valle D, Kinzler KE, Vogelstein B. 2001, New York: McGraw-Hill, 3733-3774.
3. Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ: High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet. 2006, 79 (1): 31-40. 10.1086/504601.
4. Mehta A, Beck M, Sunder-Plassmann G: Fabry Disease: Perspectives from 5 Years of FOS. 2006, Oxford: Oxford PharmaGenesis Ltd
5. Brokalaki EI, Hentschke M, Grabbe S, Jansen T: Fabry disease in a female patient due to a de novo point mutation at position 691 of exon 5. Eur J Med Res. 2006, 11 (7): 306-308.
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献